Evidence map›Paper›PMID 18696104›Full record

ArticlePflugers Archiv : European journal of physiology2009

Age-dependent differences in the inhibition of HCN2 current in rat ventricular myocytes by the tyrosine kinase inhibitor erbstatin.

Yelena Kryukova, Vitalyi O Rybin, Jihong Qu, Susan F Steinberg, Richard B Robinson

Open access · greenAbstract read
In one paragraph

Article in Pflugers Archiv : European journal of physiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Gene therapy to treat cardiovascular disease.Journal of the American Heart Association · 2013
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yelena KryukovaDepartment of Pharmacology, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, NY 10032, USA.
Vitalyi O Rybin
Jihong Qu
Susan F Steinberg
Richard B Robinson
Columbia University · US

Funding

Support CoreP01HL028958 · NHLBI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ROSEN, MICHAEL R. · 1985 to 2007
$17.6M
Protein kinase C-delta actions in cardiomyocytesR01HL077860 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI STEINBERG, SUSAN F · 2004 to 2013
$3.4M
NHLBI NIH HHS HL 28958NHLBI NIH HHS HL77860NHLBI NIH HHS P01 HL028958NHLBI NIH HHS R01 HL077860
6 · The paper itself

Abstract

Previously, we have shown that murine HCN2 channels over-expressed in newborn and adult cardiac myocytes produce currents with different biophysical characteristics. To investigate the role of tyrosine kinase modulation in these age-dependent differences, we employed the broad spectrum tyrosine kinase inhibitor erbstatin. Our results demonstrated distinct and separable effects of erbstatin on channel gating and current amplitude and a marked age dependence to these effects. In newborn myocytes, erbstatin decreased current amplitude, shifted the activation relation negative, and slowed activation kinetics. The effect on activation voltage but not that on amplitude was absent when expressing a cAMP-insensitive mutant (HCN2R/E), while a C-terminal truncated form of HCN2 (HCN2DeltaCx) exhibited only the voltage dependent but not the amplitude effect of erbstatin. Thus, the action of erbstatin on the activation relation and current amplitude are distinct and separable in newborn myocytes, and the effect on activation voltage depends on the cAMP status of HCN2 channels. In contrast to newborn myocytes, erbstatin had no effect on HCN2 under control conditions in adult myocytes but induced a negative shift with no change in amplitude when saturated cAMP was added to the pipette solution. We conclude that erbstatin's effects on HCN2 current magnitude and voltage dependence are distinct and separable, and there are fundamental developmental differences in the heart that affect channel function and its modulation by the tyrosine kinase inhibitor erbstatin.

Indexed as

Age FactorsAgingAnimalsAnimals, NewbornEnzyme InhibitorsHeart VentriclesHydroquinonesHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsIon Channel GatingIon ChannelsMyocytes, CardiacPatch-Clamp TechniquesPotassium ChannelsProtein IsoformsProtein-Tyrosine KinasesRatsEnzyme InhibitorserbstatinHcn2 protein, ratHydroquinonesHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsIon ChannelsPotassium ChannelsProtein IsoformsProtein-Tyrosine Kinases

Identifiers

PMID18696104
PMCPMC2701652
OpenAlexW2034049737

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.